Health

NIH: Major Study Finds Earlier HIV Treatment Improves Health

In this Feb. 3, 2015 file photo, Dr. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, testifies on Capitol Hill in Washington. A major international study says don’t delay in seeking HIV treatment: Starting medication soon after diagnosis helps keep people healthy longer. People who started anti-AIDS drugs while their immune system was still strong were far less likely to develop AIDS or other serious illnesses than if they waited until blood tests showed their immune system was starting to weaken, the U.S. National Institutes of Health announced Wednesday.   (AP Photo/Molly Riley, File)
In this Feb. 3, 2015 file photo, Dr. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, testifies on Capitol Hill in Washington. (AP Photo/Molly Riley, File)

LAURAN NEERGAARD, AP Medical Writer

WASHINGTON (AP) — A major international study sought to settle how soon is best to start HIV treatment — and the advice is don’t delay.

People who started anti-AIDS drugs while their immune system was strong were far less likely to develop AIDS or other serious illnesses than if they waited until blood tests showed their immune system was starting to weaken, the U.S. National Institutes of Health announced Wednesday.

The findings are preliminary, but the NIH found them so compelling that it stopped the study a year early, so that all the participants could receive medication as researchers continue to track their health.

How soon should treatment begin?

“The sooner the better,” said Dr. Anthony Fauci, director of NIH’s National Institute of Allergy and Infectious Diseases, which funded the work.

Current U.S. guidelines already recommend early treatment for HIV, but the findings could alter care recommendations in other countries.

HIV may not trigger symptoms for years, raising the question of how soon after diagnosis patients should begin taking expensive medications that may cause side effects. Previous studies have made clear that early treatment dramatically lowers the chances that someone with HIV spreads the virus to a sexual partner. But there was less evidence that the HIV patient’s own health would benefit by starting early.

The START trial — Strategic Timing of AntiRetroviral Treatment — sought proof by randomly assigning still healthy patients either to receive early therapy or to delay therapy until their CD4 cells, a key sign of immune system health, dropped into a worry zone.

While the U.S. guidelines back treatment regardless of patients’ CD4 counts, the World Health Organization’s guidelines recommend that HIV-infected people begin treatment when their CD4 levels fall below normal, to 500 or below. But that doesn’t happen in many poor countries, where often people are sicker before they receive treatment and global funding to expand care is tight.

Even in the U.S., many people don’t seek or stick with early care: The Centers for Disease Control and Prevention recently reported that only about 30 percent of Americans with HIV have the virus under control.

The START trial enrolled 4,685 people in 35 countries, all of whom had CD4 counts in the healthy range — above 500 — and had never taken anti-HIV medication. Researchers tracked deaths, the development of AIDS-related illnesses and the development of serious non-AIDS events such as cancer, heart disease and kidney or liver disease.

Over about three years, the risk of serious illness or death was reduced by 53 percent in the early treatment group, NIH said.

The actual numbers of bad outcomes in both groups were very low, given that patients were so healthy when they enrolled in the study: 41 cases in the early-treatment group compared with 86 in the group that delayed treatment until their CD4 count dropped to near 350.

The results, once final, will need careful scrutiny to see if they apply to people with the highest CD4 counts, cautioned Dr. Jay Levy of the University of California, San Francisco, who wasn’t involved in the new study.

“I’m still concerned about putting everyone on therapy,” Levy said.

But Fauci said the study offers “another reason why we should be more aggressive” in getting people tested and treated. “It tells you that you will benefit from therapy at whatever your CD4 count is,” he added.

Copyright 2015 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Tags
Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Back to top button

My News Matters to me - Washington Informer Donations

Be a Part of The Washington Informer Legacy

A donation of your choice empowers our journalists to continue the work to better inform, educate and empower you through technology and resources that you use.

Click Here Today to Support Black Press and be a part of the Legacy!

Subscribe today for free and be the first to have news and information delivered directly to your inbox.

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker